Tools
Stock profile

RESMED INC (RMD)

RMD · Latest close $242.61 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$242.61
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
0
vs previous quarter

RESMED INC (RMD) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $3.8M sold). Latest close $242.61 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 17, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-3.8M
Fundamentals
Revenue · FY2026
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Giverny Capital — 1 tracked fund hold RMD. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 6 sales ($3.8M). Insider trading

Often held alongside

BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Giverny Capital2.54%387,665ADDED (+68.5%) Q3 filed Nov 12

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +18.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

293.73178.382024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding889 of 8,857 filers
Long-only filers among them884
Change vs 2026 Q1-42 net · 806 entered · 848 exited
Shares reported, all filers99,318,112
Reported value, all filers$19.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustrySurgical & Medical Instruments & Apparatus (SIC 3841)
Revenue · FY2026$5.7B
Net income · FY2026$1.5B
Total assets · FY2026$9.0B
Shares outstanding144,252,306
Market cap (at latest close)$35.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 10, 2026.

Short interest

Shares short · Oct 15, 202611,920,328
Share of shares outstanding8.26%
Days to cover12.33

Shares short at recent settlements — Jul 31, 2026: 15.7M · Aug 14, 2026: 12.8M · Aug 31, 2026: 13.1M · Sep 15, 2026: 14.2M · Sep 30, 2026: 12.8M · Oct 15, 2026: 11.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 10, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 10K · Sep 15, 2026: 84K · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 10, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 6 sales by 4 insiders ($3.8M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 17, 2026De Witte JanSell429$237.00$101.7KSEC filing
Nov 9, 2026Farrell Michael J.Chairman and CEOSell4,993$235.35$1.2MSEC filing
Oct 23, 2026Rider Michael JGlobal General CounselSell400$255.00$102.0KSEC filing
Oct 7, 2026Farrell Michael J.Chairman and CEOSell4,991$226.33$1.1MSEC filing
Sep 8, 2026Farrell Michael J.Chairman and CEOSell4,991$222.44$1.1MSEC filing
Sep 2, 2026FARRELL PETER CSell970$234.73$227.7KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 7, 2026Farrell Michael J.Officer, Director4,991$1.1MOct 7, 2026SEC filing
Sep 8, 2026Farrell Michael J.Officer, Director4,991$1.1MSep 8, 2026SEC filing
Sep 2, 2026Peter C FarrellDirector970$227.6KSep 2, 2026SEC filing
Aug 7, 2026Farrell Michael J.Officer, Director4,991$1.0MAug 7, 2026SEC filing
Aug 5, 2026Peter C FarrellDirector8,000$1.8MAug 5, 2026SEC filing
Jul 7, 2026Farrell Michael J.Officer, Director4,991$1.1MJul 7, 2026SEC filing
Jun 8, 2026Farrell Michael J.Officer, Director4,991$968.3KJun 8, 2026SEC filing
May 27, 2026Sandercock BrettFormer Officer8,000$1.7MMay 27, 2026SEC filing
May 7, 2026Farrell Michael J.Officer, Director4,991$1.0MMay 7, 2026SEC filing
Apr 7, 2026Farrell Michael J.Officer, Director4,991$1.1MApr 7, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 7, 2026AustralianSuper Pty LtdSC 13G8,276,3815.7%Jun 30, 2026SEC filing
Apr 29, 2026Vanguard Portfolio ManagementSC 13G7,886,4895.4%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G11,961,706.28.2%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Oct 30, 2025The Vanguard GroupSC 13G/A20,007,417.413.7%Sep 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 100 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (57), Medicare/Medicaid (34), Manufacturing (7).

Federal contracts: $59.3K in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$121.4K
FY2022$0
FY2023$-62.1K
FY2024$0
FY2025$0
FY2026$0

Largest awards collected

Award IDAgencyAmountStart
75A50120C00055Department of Health and Human Services$32.0MMar 31, 2020

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Buffett — Companies with high ROE sustained for more than a decade

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Piotroski — Financial health improved over the past year

· Greenblatt Magic Formula — High earnings yield and high return on capital together

· Lynch PEG — Cheap against its growth rate

· Dividend Growth — Dividends raised for more than 10 years

· Neff Total Return Ratio — Growth plus dividends divided by P/E is high

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

Red Flags

· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)

Key figures

· Buffett — Latest ROE: 23.1% · Years ROE ≥15% (of 10): 10 · 10-yr avg ROE: 20.6% · Latest net income: $1.5B

· Growth — Latest revenue: $5.7B · 5-yr revenue CAGR: 12.1% · Straight growth years: 9

· Graham — Current ratio: 3.10 · Straight profitable years: 18 · Debt ratio: 0.36 · Latest net income: $1.5B

· Piotroski — F-score: 7 · Return on assets: 17.0% · Operating cash flow: $1.8B

· Greenblatt Magic Formula — Earnings yield: 5.0% · Return on capital: 53.7% · Combined rank: 88

· Lynch PEG — P/E: 24.24 · 5-yr EPS growth: 26.3% · PEG: 0.92

· Dividend Growth — Dividend per share: 2.40 · Dividend yield: 0.9% · Straight dividend years: 14 · 10-yr dividend growth: 81.8%

· Neff Total Return Ratio — EPS growth: 26.3% · Dividend yield: 0.9% · P/E: 24.24 · Neff ratio: 1.13

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.27 · Operating cash flow: $1.8B · Net income: $1.5B

· Auditor Change (8-K 4.01) — Latest event: Aug 17, 2026 · Events in 2 yrs: 1

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold RMD — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Oct 29, 20262.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Sep 1, 20268.01 Other EventsSEC filing
Aug 17, 20264.01 Changes in Registrant's Certifying Accountant · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on RMD

One email a week: the week’s new filings and research. Subscribe free

← RMBS  ·  RMNI →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.